Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2021 16:09 ET
|
Protara Therapeutics
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer
April 19, 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Business Overview
March 11, 2021 07:30 ET
|
Protara Therapeutics
- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End - - In Discussions with FDA on Next Steps Needed to File BLA for...
Protara Therapeutics to Participate in the Oppenheimer 31st Annual Healthcare Conference
March 10, 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
February 04, 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Appointment of Cynthia Smith to Board of Directors
February 02, 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Promotion of Jacqueline Zummo, Ph.D., to Chief Scientific Operations Officer
December 07, 2020 16:30 ET
|
Protara Therapeutics
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics to Present at Upcoming Virtual Investor Conferences
November 24, 2020 07:00 ET
|
Protara Therapeutics
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...